Response of a government hospital to prescription cost savings through its hospital formulary in Thailand

Journal of Generic Medicines

Volumn 7, Issue 4, 2010, Pages 354-361

  Burapadaja, Siriporn ^a   Chinawong, Dujrudee ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; COST CONTROL; DRUG COST; DRUG FORMULARY; HEALTH CARE AVAILABILITY; PRESCRIPTION; PUBLIC HOSPITAL; THAILAND;

EID: 78649238556     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2010.33     Document Type: Article

References (35)

1. Ess, S. M., Schneeweiss, S. and Szucs, T. D. (2003) European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21 (2): 89-103.
2. Gonsalez, J., Sismeiro, C., Dutta, S. and Stern, P. (2008) Can branded drugs benefi t from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. International Journal of Research in Marketing 25: 247-260.
3. Sun, Q., Santoro, M. A., Meng, Q., Liu, C. and Eggleston, K. (2008) Pharmaceutical policy in China. Health Affairs 27 (4): 1042-1050.
4. Gerdtham, U. G. and Lundin, D. (2004) Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics 22 (1): 29-42.
5. Martikainen, J., Kivi, I. and Linnosmaa, I. (2005) European prices of newly launched reimbursable pharmaceuticals-A pilot study. Health Policy 74: 235-246.
6. Simon, G. E., Psaty, B. M., Hrachovec, J. B. and Mora, M. (2005) Principles for evidence-based drug formulary policy. Journal of General Internal Medicine 20: 964-968.
7. Barry, M., Tilson, L. and Ryan, M. (2004) Pricing and reimbursement of drugs in Ireland. European Journal of Health Economics 5: 190-194.
8. Lee, E. K. and Malone, D. C. (2003) Comparison of peptic-ulcer drug use and expenditures before and after the implementation of a government policy to separate prescribing and dispensing practices in South Korea. Clinical Therapeutics 25 (2): 578-592.
9. Kildemoes, H. W., Christiansen, T., Gyrd-Hansen, D., Kristiansen, I. S. and Andersen, M. (2006) The impact of population ageing on future Danish drug expenditure. Health Policy 75: 298-311.
10. Thorpe, K. E. (2006) Factors accounting for the rise in health-care spending in the United States: The role of rising disease prevalence and treatment intensity. Public Health 120: 1002-1007.
11. Almarsdottir, A. B. and Traulsen, J. M. (2005) Cost-containment as part of pharmaceutical policy. Pharmacy World & Science 27 (3): 144-148.
12. Puig-Junoy, J. (2007) The impact of generic reference pricing interventions in the statin market. Health Policy 84: 14-29.
13. Brekke, K. R., Grasdal, A. L. and Holmas, T. H. (2009) Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? European Economic Review 53 (2): 170-185.
14. Hakonsen, H., Horn, A. M. and Toverud, E. L. (2009) Price control as a strategy for pharmaceutical cost containment-What has been achieved in Norway in the period 1994-2004? Health Policy 90: 277-285.
15. Folino-Gallo, P., Montilla, S., Bruzzone, M. and Martini, N. (2008) Pricing and reimbursement of pharmaceuticals in Italy. European Journal of Health Economics 9: 305-310.
16. Schneeweiss, S. (2007) Reference drug programs: Effectiveness and policy implications. Health Policy 81: 17-28.
17. Morgan, S., McMahon, M. and Greyson, D. (2008) Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia. Health Policy 87: 133-145.
18. Rocchi, F., Addis, A. and Martin, N. (2004) Current national initiatives about drug policies and cost control in Europe: The Italy example. Journal of Ambulatory Care Management 27 (2): 127-131.
19. Clercq, P. A., Hasman, A., Blom, J. A. and Korsten, H. H. M. (2001) Design and implementation of a framework to support the development of clinical guidelines. International Journal of Medical Informatics 64: 285-318.
20. Darba, J. (2003) Pharmaceutical expenditure in Spain: Evolution and cost containment measures during 1998-2001. European Journal of Health Economics 4: 151-157.
21. Petrova, G. I., Benisheva-Dimitrova, T. V., Mircheva, J. D. and Usunov, J. I. (2000) Study on essential drugs in Bulgaria: A model list based on the WHO essential drug formulary. Journal of Social and Administrative Pharmacy 17 (1): 59-63.
22. Fscher, M. A. and Avorn, J. (2003) Economic consequences of underuse of generic drugs: Evidence from medicaid and implications for prescription drug benefi t plans. Health Services Research 38 (4): 1051-1064.
23. Haas, J. S., Philips, K. A., Gerstenberger, E. P. and Seger, A. C. (2005) Potential savings from substituting generic drugs for branded-name drugs: Medical expenditure panel survey, 1997-2000. Annals of Internal Medicine 142: 891-897.
24. Tilson, L., Bennett, K. and Barry, M. (2005) The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. European Journal of Health Economics 50: 267-273.
25. Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D. and Laing, R. (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. The Lancet 373 (9659): 240-249.
26. Jamshed, S. Q., Babar, Z. U. D., Ibrahim, M. I. M. and Hassali, M A A. (2009) Generic medicines as a way to improve access and affordability: A proposed framework for Pakistan. Journal of Clinical and Diagnostic Research 3 (3): 1596-1600.
27. Wibulpolprasert, S. (ed.) (2008) Thailand Health Profi le 2005-2007, Bureau of Policy and Strategy, Ministry of Public Health. Bangkok, Thailand: Veteran Soldier Help Organization, pp. 304-306.
28. National Drug Committee. (1993) Thai National Drug Policy 1993, Thai Food Drug and Administration, Ministry of Public Health. Bangkok, Thailand: Agriculture Co-Operative Community of Thailand Printing, p. 15 (in Thai).
29. Wibulpolprasert, S., Wichai Chokwiwat, W. and Tantivess, S. (eds.) (2002) Thai Drug System. Bangkok, Thailand: Agriculture Co-operative Community of Thailand Publishing, pp. 91-92 (in Thai).
30. Health Policy in Thailand 2009. (2009) Bureau of Policy and Strategy. Ministry of Public Health, p. 32.
31. Martin, D. K., Hollenberg, D., MacRae, S., Madden, S. and Singer, P. (2003) Priority setting in a hospital drug formulary: A qualitative case study and evaluation. Health Policy 66: 295-303. (Pubitemid 37433960)
32. Buyle, F. M. and Robays, H. (2009) Evaluation of Belgian hospital drug formularies based on quality indicators. European Journal of Hospital Pharmacy Practice 15 (1): 32-37.
33. World Health Organization. (2009) WHO collaborating center for drug statistics methodology 2009, http://www.whocc.no/atcddd, accessed 19 May 2009.
34. Bryant, J. and Prohmmo, A. (2005) Payment mechanisms and prescriptions in four Thai hospitals. Health Policy 73: 160-171.
35. Akaleephana, C. et al (2009) Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: Analysis of the effect of TRIPs-plus proposal. Health Policy 91: 174-182.